Zoetis Inc. $ZTS Shares Sold by Alliance Wealth Advisors LLC UT

Alliance Wealth Advisors LLC UT reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 21.5% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 16,188 shares of the company’s stock after selling 4,430 shares during the period. Alliance Wealth Advisors LLC UT’s holdings in Zoetis were worth $2,369,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Zoetis by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock valued at $6,190,326,000 after purchasing an additional 419,777 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Zoetis by 0.9% in the second quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after buying an additional 95,294 shares during the last quarter. Norges Bank purchased a new position in shares of Zoetis in the second quarter worth about $809,491,000. Brown Advisory Inc. boosted its position in Zoetis by 5.7% during the second quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock worth $726,629,000 after acquiring an additional 250,829 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Zoetis by 113.0% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after acquiring an additional 1,995,491 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

NYSE:ZTS opened at $128.73 on Friday. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.00. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The company has a 50 day moving average price of $125.41 and a 200 day moving average price of $134.72. The stock has a market capitalization of $54.34 billion, a P/E ratio of 21.38, a PEG ratio of 1.97 and a beta of 0.96.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same period in the prior year, the firm earned $1.40 earnings per share. The firm’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is currently 35.22%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. UBS Group set a $136.00 price target on Zoetis in a research report on Thursday, January 29th. Barclays began coverage on Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price for the company. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. BTIG Research reissued a “buy” rating and set a $160.00 price target on shares of Zoetis in a research report on Wednesday, December 3rd. Finally, Stifel Nicolaus dropped their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday, November 18th. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Zoetis has a consensus rating of “Hold” and a consensus price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.